Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Rocket Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Rocket Pharmaceuticals, Inc.’s stock price such as:

• Rocket Pharmaceuticals, Inc.’s current stock price and volume
• Why Rocket Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for RCKT from analysts
• RCKT’s stock price momentum as measured by its relative strength

About Rocket Pharmaceuticals, Inc. (RCKT)

Before we jump into Rocket Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Want to learn more about Rocket Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Rocket Pharmaceuticals, Inc..

Rocket Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of January 16, 2026, 4:00 PM, CST, Rocket Pharmaceuticals, Inc.’s stock price was $3.640.

Rocket Pharmaceuticals, Inc. is down 1.89% from its previous closing price of $3.710.

During the last market session, Rocket Pharmaceuticals, Inc.’s stock traded between $3.520 and $3.740. Currently, there are approximately 111.57 million shares outstanding for Rocket Pharmaceuticals, Inc..

Rocket Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Rocket Pharmaceuticals, Inc. Stock Price History

Rocket Pharmaceuticals, Inc.’s (RCKT) price is currently up 3.7% so far this month.

During the month of January, Rocket Pharmaceuticals, Inc.’s stock price has reached a high of $4.050 and a low of $3.380.

Over the last year, Rocket Pharmaceuticals, Inc. has hit prices as high as $11.450 and as low as $2.190. Year to date, Rocket Pharmaceuticals, Inc.’s stock is up 3.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Rocket Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 16, 2026, there were 2 analysts who downgraded Rocket Pharmaceuticals, Inc.’s stock and 11 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Rocket Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Rocket Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Rocket Pharmaceuticals, Inc. (RCKT) by visiting AAII Stock Evaluator.

Relative Price Strength of Rocket Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2026, Rocket Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -17.60%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how Rocket Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Rocket Pharmaceuticals, Inc. Stock Price: Bottom Line

As of January 16, 2026, Rocket Pharmaceuticals, Inc.’s stock price is $3.640, which is down 1.89% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Rocket Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.